Chinese Protocol of Diagnosis and Treatment of Colorectal Cancer (2020 edition).
10.3760/cma.j.cn112139-20200518-00390
- Collective Name:National Health Commission of the People's Republic of China
- Publication Type:Journal Article
- Keywords:
Colorectal neoplasms;
Guidebooks
- MeSH:
China;
epidemiology;
Colorectal Neoplasms;
diagnosis;
epidemiology;
therapy;
Humans;
Practice Guidelines as Topic
- From:
Chinese Journal of Surgery
2020;58(8):561-585
- CountryChina
- Language:Chinese
-
Abstract:
Colorectal cancer (CRC) is one of the most common malignant tumors in China. In recent years, the incidence and mortality of CRC in China have been on the rise. According to the China cancer statistics report in 2018, the incidence and mortality of CRC in China ranked the third and fifth among all malignant tumors, with 376,000 new cases and 191,000 deaths. China has become the country with the highest number of new cases and deaths of CRC every year in the world, which seriously threatens the health of Chinese residents. In 2010, the National Ministry of Health organized colorectal cancer expertise of the Chinese Medical Association to write the Chinese Protocol of Diagnosis and Treatment of Colorectal Cancer (2010 edition) and publish it publicly. Since 2010, the National Health and Family Planning Commission has organized experts to revise the protocol in 2015 and 2017, while the National Health Commission revised it in 2020. The revised part of Chinese Protocol of Diagnosis and Treatment of Colorectal Cancer (2020 edition) involves new progress in the field of imaging examination, pathological evaluation, surgery, chemotherapy and radiotherapy. The 2020 edition of the protocol not only referred to the contents of the international guidelines, but also combined with the specific national conditions and clinical practice in China, and also included many evidence-based clinical data in China recently. The 2020 edition of the protocol would further promote the standardization of diagnosis and treatment of CRC in China, improve the survival and prognosis of patients, and benefit millions of CRC patients and their families.
